Literature DB >> 30712090

MRI-targeted biopsies: What's next?

Guillaume Ploussard1,2, Alberto Briganti3.   

Abstract

Mesh：

Year:  2019        PMID： 30712090     DOI： 10.1007/s00345-019-02659-0

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  13 in total

1.  Extra-target low-risk prostate cancer: implications for focal high-intensity focused ultrasound of clinically significant prostate cancer.

Authors:  A Annoot; J Olivier; P Valtille; V Deken; X Leroy; P Puech; A Villers
Journal:  World J Urol       Date:  2018-08-16       Impact factor: 4.226

Review 2.  Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy.

Authors:  Paolo Dell'Oglio; Armando Stabile; Brendan Hermenigildo Dias; Giorgio Gandaglia; Elio Mazzone; Nicola Fossati; Vito Cucchiara; Emanuele Zaffuto; Vincenzo Mirone; Nazareno Suardi; Alexandre Mottrie; Francesco Montorsi; Alberto Briganti
Journal:  World J Urol       Date:  2018-06-09       Impact factor: 4.226

3.  Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies.

Authors:  François Cornud; Mathieu Roumiguié; Nicolas Barry de Longchamps; Guillaume Ploussard; Eric Bruguière; Daniel Portalez; Bernard Malavaud
Journal:  Radiology       Date:  2018-01-22       Impact factor: 11.105

Review 4.  Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?

Authors:  Samuel A Gold; Graham R Hale; Jonathan B Bloom; Clayton P Smith; Kareem N Rayn; Vladimir Valera; Bradford J Wood; Peter L Choyke; Baris Turkbey; Peter A Pinto
Journal:  World J Urol       Date:  2018-05-21       Impact factor: 4.226

5.  Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies.

Authors:  Bertrand Covin; Mathieu Roumiguié; Marie-Laure Quintyn-Ranty; Pierre Graff; Jonathan Khalifa; Richard Aziza; Guillaume Ploussard; Daniel Portalez; Bernard Malavaud
Journal:  World J Urol       Date:  2018-08-25       Impact factor: 4.226

6.  A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial.

Authors:  James S Wysock; Andrew B Rosenkrantz; William C Huang; Michael D Stifelman; Herbert Lepor; Fang-Ming Deng; Jonathan Melamed; Samir S Taneja
Journal:  Eur Urol       Date:  2013-11-08       Impact factor: 20.096

Review 7.  Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?

Authors:  Guillaume Ploussard; Hendrik Borgmann; Alberto Briganti; Pieter de Visschere; Jurgen J Fütterer; Giorgio Gandaglia; Isabel Heidegger; Alexander Kretschmer; Romain Mathieu; Piet Ost; Prasanna Sooriakumaran; Cristian Surcel; Derya Tilki; Igor Tsaur; Massimo Valerio; Roderick van den Bergh
Journal:  World J Urol       Date:  2018-07-02       Impact factor: 4.226

8.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

9.  Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided? A pilot study.

Authors:  Jonathan Olivier; Veeru Kasivisvanathan; Elodie Drumez; Jean-Christophe Fantoni; Xavier Leroy; Philippe Puech; Arnauld Villers
Journal:  World J Urol       Date:  2018-07-23       Impact factor: 4.226

10.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.